Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
ETFs with BIIB as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|8.98%||iShares Nasdaq Biotechnology Index Fund (IBB)||-53.18 (-16.27%)|
|6.14%||VanEck Vectors Biotech ETF (BBH)||-15.30 (-12.37%)|
|5.78%||PowerShares Dynamic Biotech &Genome (PBE)||-9.37 (-19.09%)|
|5.07%||VanEck Vectors Morningstar Wide Moat ETF (MOAT)||+4.09 (14.25%)|
|4.15%||PowerShares Dynamic Pharmaceuticals (PJP)||-4.57 (-6.69%)|
Company Description (as filed with the SEC)
Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group), which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies. ... More ...
Where does BIIB fit in the risk graph?
|Annual EPS Est:||$17.01|
|Quarterly EPS Est:||4.67|